Abstract 522P
Background
Adding an immune checkpoint inhibitor (ICI) to chemotherapy has demonstrated efficacy in treating extensive-stage small cell lung cancer (ES-SCLC). However, patients with idiopathic interstitial pneumonia (IIP) have a higher risk of developing pneumonitis associated with anticancer therapy. We conducted a multicenter, single-arm trial to evaluate the safety and efficacy of durvalumab plus etoposide and carboplatin for patients with ES-SCLC and mild IIP.
Methods
Eligible patients were those who had not been previously treated with ES-SCLC and mild IIPs. Mild IIP was defined as predicted vital capacity (VC) ≥80%; no collagen vascular disease-associated antibodies; and chest high-resolution computed tomography image revealed a probable UIP, indeterminate for UIP, or alternative diagnosis pattern. The primary endpoint was severe-pneumonitis-free (SPF) rate, which was defined as the rate of patients who did not develop Grade 3 or higher pneumonitis. The study treatment was feasible if the SPF rate was 90% or more, and grade 5 pneumonitis was found within one patient.
Results
In total, 22 cases were enrolled, and 21 were included in the analysis. The median age was 74 years (range, 65–82). Most patients had stage Ⅳ disease (90%) and Eastern Cooperative Oncology Group Performance Status of 1 (67%). The median %VC was 96.1% (range 81.3–117.8). Thirteen patients displayed a probable UIP pattern, while 8 were indeterminate for UIP pattern. The SPF rate was 95.2% (20/21). The incidence of pneumonitis was 9.5% (2/21) for all grades. One patient had grade 5 pneumonitis.
Conclusions
Durvalumab plus etoposide and carboplatin can be a feasible treatment option for patients with ES-SCLC and mild IIPs.
Clinical trial identification
The Japan Registry of Clinical Trials: jRCTs051200109.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca PLC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract